Clinical Trial Update: Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update showing termination of a real-world study comparing adding a single injection of Apidra to once-daily Lantus versus a twice-daily …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Apidra (insulin glulisine)
• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: TERMINATED